An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Trial Profile

An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Dexpramipexole (Primary)
  • Indications Hypereosinophilic syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 02 Dec 2017 Planned End Date changed from 28 Feb 2018 to 23 Oct 2019.
    • 29 Dec 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2016.
    • 22 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top